Arkolith/Insider Trading/NMRA/Form 4

Berns Paul L

See Remarks, DirectorNeumora Therapeutics, Inc. (NMRA) · full profile →Form 4 · filed May 30, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
0 non-derivative · 8 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 28, 2025Disposed to issuer(D)956K——0
May 28, 2025Disposed to issuer(D)343K——0
May 28, 2025Grant(A)2.0M——2.0M
May 28, 2025Grant(A)497K——497K
May 28, 2025Grant(A)956K——956K
May 28, 2025Grant(A)343K——343K
May 28, 2025Disposed to issuer(D)497K——0
May 28, 2025Disposed to issuer(D)2.0M——0

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-079920) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Neumora Therapeutics, Inc.

Build

Ask your agent about NMRA insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0000950170-25-079920"
Ask your agent
Use Arkolith to summarize insider buying and selling at Neumora Therapeutics, Inc.
over the last 90 days and cite the filings.